OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

PHASE3ACTIVE_NOT_RECRUITING

This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine therapy in combination with a CDK4/6 inhibitor.

Study details:

This is an international, multicenter, randomized, open-label, active-controlled, phase 3 clinical trial. The purpose of this trial is to compare the safety and efficacy of palazestrant (OP-1250) as a single agent to the standard of care endocrine therapy: either fulvestrant or an aromatase inhibitor (anastrozole, letrozole, or exemestane). This trial is seeking adult participants with ER+, HER2- advanced or metastatic breast cancer whose disease has relapsed or progressed on 1 or 2 prior lines of standard-of-care endocrine therapy for metastatic breast cancer.

Prior lines of therapy must include one line of endocrine therapy in combination with a CDK 4/6 inhibitor. In the dose-selection part of the trial, approximately 120 participants will be randomized to one of the two doses of palazestrant or to the standard-of-care endocrine therapy. Thereafter, approximately 390 participants will be randomized to palazestrant at the selected dose or to the standard-of-care endocrine therapy.

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

  1. Adult female or male participants.
  2. ER+, HER2- locally advanced or metastatic breast cancer that is not amenable to curative therapy.
  3. Evaluable disease (measurable disease or bone-only disease).
  4. Previously received a CDK4/6 inhibitor in combination with an endocrine therapy in the advanced setting. One additional line of ET as a monotherapy is allowed. Duration of the most recent prior ET must be at least 6 months.
  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  6. Adequate hematologic, hepatic, and renal functions.
  7. Female participants can be pre-, peri- or postmenopausal.
  8. Male and pre- or peri-menopausal female participants must be willing to take a GnRH (or LHRH) agonist.

Exclusion criteria

  1. Symptomatic visceral disease, imminent organ failure, or any other reason that makes the participant ineligible for endocrine monotherapy.
  2. Previously received chemotherapy in the advanced/metastatic setting.
  3. Previously received treatment with elacestrant or an investigational estrogen receptor-directed therapy.
  4. History of allergic reactions to study treatment.
  5. Any contraindications to the selected standard-of-care endocrine therapy in the local prescribing information.
  6. Symptomatic central nervous system metastases, carcinomatous meningitis, leptomeningeal disease, or a spinal cord compression that require immediate treatment.
  7. Clinically significant comorbidities such as significant cardiac or cerebrovascular disease, gastrointestinal disorders that could affect absorption of study treatment.

Eligibility

Age eligible for study : NA

Healthy volunteers accepted : No

Gender eligible for study: ALL

Things to know

Study dates

Study start:

Primary completion:

Study completion finish:

study type

Study type

TREATMENT

phase

Phase

    PHASE3

trial

Study ID

NCT06016738

Intervention or treatment

DRUG: Palazestrant

DRUG: Fulvestrant

DRUG: Anastrozole

DRUG: Letrozole

DRUG: Exemestane

Conditions

  • Breast Cancer
  • Advanced Breast Cancer
  • Metastatic Breast Cancer
  • ER Positive Breast Cancer
  • HER2 Negative Breast Carcinoma
  • Condition: Breast Cancer, Advanced Breast Cancer and more

  • DRUG: Palazestrant and other drugs

  • Gosford, New South Wales, Australia and more

  • Sponsor: Olema Pharmaceuticals, Inc.

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial?

If you're a clinic or sponsor, you can claim this study

Research sites nearby

Closest Location:

Clinical Trial Site

Select from list below to view details:

  • Clinical Trial Site

    Gosford, New South Wales, Australia

  • Clinical Trial Site

    Westmead, New South Wales, Australia

  • Clinical Trial Site

    Adelaide, South Australia, Australia

  • Clinical Trial Site

    Ballarat Central, Victoria, Australia

Loading map...

Who is running the clinical trial?

OPI

Olema Pharmaceuticals, Inc.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: Palazestrant (OP-1250)
  • Participants will receive Palazestrant
Drug: Palazestrant
    ACTIVE_COMPARATOR: Standard of Care Endocrine Therapy
    • Participants will receive Investigator's choice of one of the Standard of Care drugs (fulvestrant, anastrozole, letrozole, or exemestane)
    Drug: Fulvestrant, Drug: Anastrozole, Drug: Letrozole, Drug: Exemestane

      What is the study measuring?

      Primary Outcome

      MeasureDescriptionTime Frame
      Dose-Selection Part: Incidence of adverse eventsTo evaluate the number of participants with adverse eventsFrom Date of Randomization up to 16 weeks
      Dose-Selection Part: Incidence of dose reductionTo evaluate the number of participants reducing the dose of palazestrantFrom Date of Randomization up to 16 weeks
      Dose-Selection Part: Incidence of drug discontinuationTo evaluate the number of participants discontinuing palazestrantFrom Date of Randomization up to 16 weeks
      Trial: Progression-Free Survival (PFS)To compare PFS, based on a Blinded Independent Review Committee (BIRC) assessment, between arms of OP-1250 and standard-of-care treatment. This will be assessed separately in populations of ESR1-mutation detected and ESR1-mutation not detected participants.From Date of Randomization until Disease Progression or Death Due to Any Cause (estimated as up to 2 years)

      Secondary Outcome

      MeasureDescriptionTime Frame
      Trial: Overall Survival (OS)To compare OS between arms of OP-1250 and standard-of-care treatment. This will be assessed separately in populations of ESR1 mutation detected and ESR1 mutation not detected participants.From Date of Randomization until Death Due to Any Cause (estimated as up to 4 years)
      Are you running this trial?If you're a clinic or sponsor, you can claim this study.

      References

      Clinical Trials Gov: OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

      Other trials to consider

      Loading suggested trials...

      Top searched conditions